Abstract
Background The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (NSCLC) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with NSCLC, as well as for patients progressing after treatment with epidermal growth factor receptor (EGFR) inhibitors, is the standard of care in Canada and many parts of the world. Methods A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for EGFR, anaplastic lymphoma kinase (ALK), ROS1, BRAF V600 and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and EGFR T790M upon progression. As well, additional exploratory molecules and targets are likely to impact future patient care, including MET exon 14 skipping mutations and whole gene amplification, RET translocations, HER2 (ERBB2) mutations, NTRK, RAS (KRAS and NRAS), as well as TP53. Results The standard of care must include the incorporation of testing for novel biomarkers as they become available, as it will be difficult for national guidelines to keep pace with technological advances in this area. Conclusions Canadian patients with NSCLC should be treated equally; the minimum standard of care is defined in this paper.
| Original language | English |
|---|---|
| Pages (from-to) | 73-82 |
| Number of pages | 10 |
| Journal | Current Oncology |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 |
Bibliographical note
Funding Information:We have read and understood Current Oncology’s policy on conflicts of interest disclosure and declare the following interests: BM has received honoraria from Boehringer Ingelheim, Eli Lily, Pfizer, Roche, Merck, Bristol-Myers Squibb, Novartis, and AstraZeneca. She is in a consulting/advisory role with Boehringer Ingelheim, her institution has received research funding from Roche and Bayer and she has received travel/accommodations/expenses from Boehringer Ingelheim, AstraZeneca, Novartis, and Pfizer. NB has received consulting honoraria from Boehringer Ingelheim, Eli Lily, Pfizer, Roche, Merck, Bristol-Myers Squibb, Novartis, Sanofi, AstraZeneca and a research grant from Merck; PC has received honoraria from Boehringer Ingelheim, Eli Lily, Pfizer, Roche, Merck, Bristol-Myers Squibb, Novartis, AstraZeneca, research grants from Boehringer Ingelheim, Hoffmann La Roche, and AstraZeneca, and institutional educational grants from EMD Serono, Merck and Pfizer; CC has received consulting honoraria from Boehringer Ingel-heim, Eli Lily, Pfizer, Roche, Merck, Bristol-Myers Squibb, Novartis, and AstraZeneca and research grants from Pfizer and Merck; RJ has received consulting honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, EMD Serono, Merck, Novartis, Pfizer, and Roche and a research grant from Bristol Myers Squibb and Merck; SKR has received honoraria from Astra-Zeneca, Novartis, Pfizer, Roche, and Bristol-Myers Squibb and research grant funding from Pfizer, Astra-Zeneca, Novartis, and Bristol-Myers Squibb; MST has received honoraria from Pfizer, Ventana/Roche, Merck, AstraZen-eca, and Bristol-Myers Squibb and research grants from Pfizer, Merck, and AstraZeneca; PWP has received honoraria from Boehringer Ingelheim, Merck, Astra Zeneca, Bristol-Myers Squibb, Lilly, and Novartis; ZX has received honoraria and grants from Pfizer, Roche, Merck, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Novartis, and Eli Lily; DNI has received honoraria from Boehringer Ingelheim, Eli Lily, Pfizer, Roche, Merck, Bristol-Myers Squibb, Novartis, and AstraZeneca.
Funding Information:
Funding for this project was provided by Lung Cancer Canada, a national charitable organization that serves as Canada’s leading resource for lung cancer education, patient support, and advocacy. Based in Toronto, Lung Cancer Canada is a member of the Global Lung Cancer Coalition and is the only organization in Canada focused exclusively on lung cancer. Lung Cancer Canada provided funding to a medical writer, Chrystal Palaty, to assist the authors with writing, editing, and submission of the manuscript. The authors wish to thank Dr. Samar Tabchi for thoroughly reviewing this article.
Publisher Copyright:
© 2018 Multimed Inc.
ASJC Scopus Subject Areas
- Oncology
